CJC-1295 vs Sermorelin
Modified longer-acting GHRH vs native fragment.
| Attribute | CJC-1295 GHRH analog | Sermorelin GHRH(1-29) |
|---|---|---|
| Category | Muscle Growth & Performance | Muscle Growth & Performance |
| Best known for | Sustained GHRH stimulation research | Endogenous GH-release research |
| In plain English | If ipamorelin opens the GH faucet, CJC-1295 widens the pipe. Together they produce larger natural GH pulses. | The original GH peptide. Sermorelin is shorter-acting and milder than CJC-1295 — researchers consider it the gentle introduction to GH peptide research. |
| How it works | Activates the GHRH receptor in the pituitary, increasing the amplitude of natural GH pulses. | Stimulates pituitary GH release by binding the GHRH receptor. |
| Researchers study | GH secretion, IGF-1 levels, body composition, and sleep architecture. | Age-related GH decline, body composition, sleep, and pediatric GH deficiency. |
| Internet discussion | DAC vs no-DAC is the eternal forum debate. | Older audience favors it for being well-studied with a long history. |
CJC-1295
Sustained GHRH stimulation research
If ipamorelin opens the GH faucet, CJC-1295 widens the pipe. Together they produce larger natural GH pulses.
Activates the GHRH receptor in the pituitary, increasing the amplitude of natural GH pulses.
GH secretion, IGF-1 levels, body composition, and sleep architecture.
DAC vs no-DAC is the eternal forum debate.
CJC-1295 is a GHRH analog that amplifies natural GH pulses, especially when paired with a ghrelin mimetic.
Sermorelin
Endogenous GH-release research
The original GH peptide. Sermorelin is shorter-acting and milder than CJC-1295 — researchers consider it the gentle introduction to GH peptide research.
Stimulates pituitary GH release by binding the GHRH receptor.
Age-related GH decline, body composition, sleep, and pediatric GH deficiency.
Older audience favors it for being well-studied with a long history.
Sermorelin is the original GHRH analog with the longest research history in GH peptide work.

